The expression of E-Cadherin in GBM patient specimens is associated with poor prognosis and a subset of E-Cadherin expressing CD133+ GSCs may have the capacity to transdifferentiate into endothelial cells. The gene discussed is CDH1; the disease is glioblastoma.